Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05107856 | PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies | terminated | Phase 1 | 21 | Prelude TherapeuticsINDUSTRY | 1 | Jan 31, 2024 | clinicaltrials |
| NCT02152956 | Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)(VOYAGE) | terminated | Phase 1 / Phase 2 | 244 | MacroGenicsINDUSTRY | 8 | Jan 30, 2024 | clinicaltrials |
| NCT04092179 | Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers | terminated | Phase 1 / Phase 2 | 27 | University Health Network, TorontoOTHER | 1 | Jan 24, 2024 | clinicaltrials |
| NCT04196010 | Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms | terminated | Phase 1 | 13 | University of WashingtonOTHER | 1 | Dec 28, 2023 | clinicaltrials |
| NCT05066165 | Study Investigating NTLA-5001 in Subjects With Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 6 | Intellia TherapeuticsINDUSTRY | 2 | Dec 28, 2023 | clinicaltrials |
| NCT00540995 | Busulfan, Etoposide, and Intensity-Modulated Radiation Therapy Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer | terminated | Phase 1 / Phase 2 | 25 | City of Hope Medical CenterOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03904251 | CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia | terminated | Phase 1 | 13 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04023071 | FT516 in Subjects With Advanced Hematologic Malignancies | terminated | Phase 1 | 72 | Fate TherapeuticsINDUSTRY | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03690154 | A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML | terminated | Phase 1 | 67 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 2 | Oct 13, 2023 | clinicaltrials |
| NCT02743611 | Safety & Activity of Controllable PRAME-TCR Therapy in Previously Treated AML/MDS or Metastatic Uveal Melanoma | terminated | Phase 1 / Phase 2 | 4 | Bellicum PharmaceuticalsINDUSTRY | 1 | Oct 5, 2023 | clinicaltrials |
| NCT04614636 | FT538 in Subjects With Advanced Hematologic Malignancies | terminated | Phase 1 | 42 | Fate TherapeuticsINDUSTRY | 1 | Sep 21, 2023 | clinicaltrials |
| NCT05144334 | A Study of BTX-1188 in Subjects With Advanced Malignancies | terminated | Phase 1 | 8 | Biotheryx, Inc.INDUSTRY | 1 | Sep 18, 2023 | clinicaltrials |
| NCT04079738 | Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib | terminated | Phase 1 / Phase 2 | 8 | H Scott BoswellOTHER | 1 | Sep 13, 2023 | clinicaltrials |
| NCT04679194 | Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML/MDS After HSCT | terminated | Phase 1 | 11 | Mana TherapeuticsINDUSTRY | 1 | Jun 18, 2023 | clinicaltrials |
| NCT02882321 | Oxidative Phosphorylation Inhibitor IACS-010759 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 17 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT03634228 | Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT02440685 | A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 51 | Asana BioSciencesINDUSTRY | 2 | Jun 7, 2023 | clinicaltrials |
| NCT05077423 | A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 3 | Y-mAbs TherapeuticsINDUSTRY | 1 | May 30, 2023 | clinicaltrials |
| NCT02203773 | Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine (Chemo Combo) in Subjects With Acute Myelogenous Leukemia (AML) | terminated | Phase 1 | 212 | AbbVieINDUSTRY | 4 | May 16, 2023 | clinicaltrials |
| NCT05256277 | NK Cell Therapy for AML | terminated | Phase 1 | 3 | Zhejiang UniversityOTHER | 1 | May 16, 2023 | clinicaltrials |
| NCT03465540 | Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies | terminated | Phase 1 | 24 | AmgenINDUSTRY | 6 | Apr 12, 2023 | clinicaltrials |
| NCT03878927 | CPX-351+GO in Subjects 55 Years Old, or Older, With AML(CPX GO) | terminated | Phase 1 | 11 | Weill Medical College of Cornell UniversityOTHER | 1 | Mar 10, 2023 | clinicaltrials |
| NCT02543749 | DC Vaccination in CML | terminated | Phase 1 / Phase 2 | 1 | Charite University, Berlin, GermanyOTHER | 1 | Feb 9, 2023 | clinicaltrials |
| NCT05223699 | Study of MGTA-117 in Patients With Adult Acute Myeloid Leukemia (AML) and Myelodysplasia-Excess Blasts (MDS-EB) | terminated | Phase 1 | 22 | Magenta Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2023 | clinicaltrials |
| NCT02323113 | Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML) | terminated | Phase 1 / Phase 2 | 43 | Calithera Biosciences, IncINDUSTRY | 2 | Feb 8, 2023 | clinicaltrials |
| NCT02393248 | Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) | terminated | Phase 1 / Phase 2 | 201 | Incyte CorporationINDUSTRY | 2 | Jan 6, 2023 | clinicaltrials |
| NCT00887926 | Study of IMC-EB10 in Participant With Leukemia | terminated | Phase 1 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Dec 22, 2022 | clinicaltrials |
| NCT04402723 | Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | terminated | Phase 1 | 8 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT04866056 | Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. | terminated | Phase 1 / Phase 2 | 1 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Dec 1, 2022 | clinicaltrials |
| NCT03214666 | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | terminated | Phase 1 / Phase 2 | 12 | GT Biopharma, Inc.INDUSTRY | 1 | Nov 10, 2022 | clinicaltrials |
| NCT04496999 | HDM201 and Midostaurin (HDMM) in Relapsed/Refractory AML With FLT3mut and TP53wt.(HDMM) | terminated | Phase 1 | 2 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03516760 | Dose-escalating Phase I Trial With GEM333 in Patients With Acute Myeloid Leukemia | terminated | Phase 1 | 36 | AvenCell Europe GmbHINDUSTRY | 1 | Sep 29, 2022 | clinicaltrials |
| NCT03218683 | Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. | terminated | Phase 1 | 70 | AstraZenecaINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT02267863 | A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS | terminated | Phase 1 | 21 | Aptose Biosciences Inc.INDUSTRY | 1 | Aug 22, 2022 | clinicaltrials |
| NCT03760666 | A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Clear Creek Bio, Inc.INDUSTRY | 1 | Aug 8, 2022 | clinicaltrials |
| NCT02773732 | Clinical Trial of Oral Ciprofloxacin and Etoposide in Subjects With Resistant Acute Myeloid Leukemia (AML)(UF-AML-CE-101) | terminated | Phase 1 / Phase 2 | 11 | University of FloridaOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01014546 | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis | terminated | Phase 1 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT01550185 | Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia | terminated | Phase 1 | 10 | Roswell Park Cancer InstituteOTHER | 1 | Jul 22, 2022 | clinicaltrials |
| NCT05001451 | Study of GDX012 in Patients With MRD Positive AML | terminated | Phase 1 | 3 | GammaDelta Therapeutics LimitedINDUSTRY | 1 | Jul 20, 2022 | clinicaltrials |
| NCT01640301 | Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant | terminated | Phase 1 / Phase 2 | 47 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 14, 2022 | clinicaltrials |
| NCT04006847 | Omega -3 Fatty Acid in Combination With Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 1 | Milton S. Hershey Medical CenterOTHER | 1 | Jul 1, 2022 | clinicaltrials |
| NCT03552029 | Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML) | terminated | Phase 1 | 10 | Daiichi SankyoINDUSTRY | 1 | May 20, 2022 | clinicaltrials |
| NCT03217838 | Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. | terminated | Phase 1 | 50 | AstraZenecaINDUSTRY | 2 | Apr 5, 2022 | clinicaltrials |
| NCT01187810 | Fenretinide in Children With Recurrent/Resistant ALL, AML, and NHL | terminated | Phase 1 | 3 | South Plains Oncology ConsortiumNETWORK | 1 | Mar 31, 2022 | clinicaltrials |
Data updated 22 days agoSource updated Jan 31, 2024source: clinicaltrials